用于评估聚乙二醇400/水和吐温80/水体系中药物制剂前风险的计算机模拟模型的开发与验证
Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems.
作者信息
Crivori Patrizia, Morelli Amedea, Pezzetta Daniele, Rocchetti Maurizio, Poggesi Italo
机构信息
Pharmacokinetic & Modeling/Modeling, Accelera, Nerviano Medical Sciences, viale Pasteur 10, 20014 Nerviano, Italy.
出版信息
Eur J Pharm Sci. 2007 Nov;32(3):169-81. doi: 10.1016/j.ejps.2007.06.008. Epub 2007 Aug 21.
Solubility is one of the most important properties of drug candidates for achieving the targeted plasma concentrations following oral dosing. Furthermore, the formulations adopted in the in vivo preclinical studies, for both oral and intravenous administrations, are usually solutions. To formulate compounds sparingly soluble in water, pharmaceutically acceptable cosolvents or surfactants are typically employed to increase solubility. Compounds poorly soluble also in these systems will likely show severe formulation issues. In such cases, relatively high amount of compounds, rarely available in the early preclinical phases, are needed to identify the most appropriate dosing vehicles. Hence, the purpose of this study was to build two computational models which, on the basis of the molecular structure, are able to predict the compound solubility in two vehicle systems (40% PEG400/water and 10% Tween80/water) used in our company as screening tools for anticipating potential formulation issues. The two models were developed using the solubility data obtained from the analysis of approximately 2000 chemically diverse compounds. The structural diversity and the drug-like space covered by these molecules were investigated using the ChemGPS methodology. The compounds were classified (high/low preformulation risk) based on the experimental solubility value range. A combination of descriptors (i.e. logD at two different pH, E-state indices and other 2D structural descriptors) was correlated to these classes using partial least squares discriminant (PLSD) analysis. The overall accuracy of each PLSD model applied to independent sets of compounds was approximately 78%. The accuracy reached when the models were used in combination to identify molecules with low preformulation risk in both systems was 83%. The models appeared a valuable tool for predicting the preformulation risk of drug candidates and consequently for identifying the most appropriate dosing vehicles to be further investigated before the first in vivo preclinical studies. Since only a small number of 2D descriptors is need to evaluate the preformulation risk classes, the models resulted easy to use and characterized by high throughput.
溶解度是候选药物最重要的性质之一,对于口服给药后达到目标血浆浓度至关重要。此外,体内临床前研究中采用的口服和静脉给药制剂通常为溶液剂。为了配制难溶于水的化合物,通常使用药学上可接受的助溶剂或表面活性剂来增加溶解度。在这些体系中也难溶的化合物可能会出现严重的制剂问题。在这种情况下,需要相对大量的化合物(在临床前早期阶段很少能获得)来确定最合适的给药载体。因此,本研究的目的是建立两个计算模型,这两个模型能够基于分子结构预测化合物在两种载体体系(40%聚乙二醇400/水和10%吐温80/水)中的溶解度,这两种体系是我们公司用作筛选工具以预测潜在制剂问题的。这两个模型是利用从大约2000种化学结构不同的化合物分析中获得的溶解度数据开发的。使用ChemGPS方法研究了这些分子的结构多样性和类药空间。根据实验溶解度值范围对化合物进行分类(高/低制剂前风险)。使用偏最小二乘判别(PLSD)分析将描述符组合(即两种不同pH下的logD、E态指数和其他二维结构描述符)与这些类别相关联。应用于独立化合物集的每个PLSD模型的总体准确率约为78%。当两个模型结合使用以识别在两种体系中制剂前风险低的分子时,准确率达到83%。这些模型似乎是预测候选药物制剂前风险的有价值工具,因此对于在首次体内临床前研究之前确定要进一步研究的最合适给药载体很有用。由于只需少量二维描述符就能评估制剂前风险类别,这些模型使用起来很方便且具有高通量的特点。